Norditropin Daily denied due to quantity / dose limits by UnitedHealthcare?

UnitedHealthcare requires prior authorization for Norditropin (daily somatropin) under its Commercial growth hormone policy, and defines an "essential" use of growth hormone as therapy to treat a deficiency as part of chronic disease management, distinguishing it from non-essential replacement uses . Covered indications follow FDA labeling and include Congenital Growth Hormone Deficiency (GHD), Pediatric GHD, Transition Phase Adolescent GHD, Adult GHD, and Prader-Willi Syndrome , with additional pediatric indications such as short stature born small for gestational age (SGA) with no catch-up growth by age 2 to 4, and Idiopathic Short Stature (ISS) with height SDS less than -2.25 and growth rates unlikely to permit attainment of adult height in the normal range . Authorization is issued for 12 months at a time , and for transition adolescents the criteria apply during the period from mid to late teens until 6 to 7 years after achievement of adult height . Contraindications per labeling include acute critical illness after open heart or abdominal surgery or multiple accidental trauma, pediatric patients with Prader-Willi syndrome who are severely obese or have upper airway obstruction/sleep apnea, hypersensitivity to somatropin or excipients, and active proliferative or severe non-proliferative diabetic retinopathy . Benefit caps may apply: if the diagnosis is essential the cap is overridden, but if non-essential only the authorization applies and supply limits may be in place . Adult GHD diagnosis typically requires biochemical confirmation (e.g., Insulin Tolerance Test less than 5 ng/mL as the test of choice ) and an endocrinologist must coordinate therapy.

- Submit complete biochemical workup: two failed GH provocative stimulation tests for pediatric GHD per Pediatric Endocrine Society (Grimberg et al., 2016) guidelines, or for adults the Endocrine Society 2011 guideline (Molitch et al.) and AACE/ACE 2019 guideline ( College of endocrinology guidelines for management of growth hormone deficiency in adults and patients transitioning from pediatric to adult care, Endocr Pract 2019;25(11):1191-1232 ) which support diagnosis with documented pituitary/hypothalamic disease plus low IGF-1 - Provide growth charts demonstrating height SDS and growth velocity, citing Pediatric Endocrine Society guidelines providing recommendations for the clinical management of children and adolescents with growth failure ; if transition-age, cite AACE 2019 transition guidance for retesting - Document open epiphyses by X-ray and ongoing growth velocity >2 cm/year, or document clinical reason for slower response (e.g., late puberty), aligned with Pediatric Endocrine Society recommendations - Confirm prescription is written or co-managed by a board-certified endocrinologist with attestation letter - Demonstrate that contraindications do not apply (e.g., negative sleep study and BMI documentation for PWS patients, ophthalmologic clearance for diabetics, no active neoplasm) per Norditropin prescribing information - Argue essential-use designation: GHD as replacement for a chronic pituitary disease meets UHC's own definition of "therapy to treat a deficiency as part of chronic disease management" , which should override benefit caps - For adult continuation, submit IGF-1 normalization, improvement in body composition, lipid profile, and quality-of-life scores (AGHDA) supporting clinical benefit per Endocrine Society guideline ( Molitch ME et al., Evaluation and treatment of adult growth hormone deficiency: an Endocrine Society clinical practice guideline, J Clin Endocrinol Metab )

## Why UnitedHealthcare Caps Norditropin Quantity — and How the Math Actually Works

A quantity-limit (QL) denial on Norditropin FlexPro under UnitedHealthcare is rarely about whether somatropin is covered — coverage is usually already approved under the Commercial Medical Benefit Drug Policy: Human Growth Hormone – Somatropin. The denial is a downstream edit applied by OptumRx (UHC's PBM channel) that converts the patient's documented weight and FDA-labeled mg/kg/day ceiling for the approved indication into a maximum monthly mg, then rejects any fill exceeding that ceiling. For Pediatric GHD the conversion uses 0.024–0.034 mg/kg/day; for SGA, ISS, Turner and Noonan the FDA ceiling jumps to 0.067 mg/kg/day; Adult GHD caps at 0.05 mg/kg/day with a 0.15–0.3 mg/day starter dose. If the script was written at adult-style flat dosing without the kg math attached, Optum's edit fires automatically — even when the underlying PA is active.

The break point is almost always a stale or missing weight. UHC's policy issues authorizations for 12 months, but the QL edit recomputes against whatever weight is in the most recent clinical note Optum has on file. A pediatric patient who has gained 4 kg since the original PA, or an adult titrated up based on IGF-1 response, will trip the cap unless the prescriber resubmits via the OptumRx Prior Authorization portal (not the medical benefit portal) with a fresh weight, indication-specific mg/kg/day citation from the Norditropin label, and the calculated weekly mg. For Adult GHD, attach the ITT result (<5 ng/mL is the policy's test of choice) plus the endocrinologist coordination note — Optum reviewers will downgrade a script signed by a generalist.

Regulatory levers matter when Optum stonewalls. Under 29 CFR §2560.503-1(g), UHC must disclose the specific QL calculation, the weight on file, and the policy version it relied on — a generic "exceeds quantity limit" letter is non-compliant and supports a DOL or state DOI escalation. 45 CFR §156.122(b) prohibits ACA plans from using formulary design (including QLs) to discriminate against a covered condition, and a QL that effectively blocks FDA-labeled dosing for a recognized indication is a parity argument. Pinto v. Aetna Life Ins. Co. (10th Cir. 2014) places the burden on the insurer to justify restrictions when the requested therapy is within label — useful framing if Optum claims the dose is "experimental" rather than simply over-cap.

Tactical tip: Don't appeal the QL as written. Resubmit a new PA with weight-of-today, the exact FDA mg/kg/day citation for the indication, and a one-line dose calculation in the cover sheet. Optum's QL edit re-evaluates against the new PA in 24–72 hours, bypassing the 30-day appeal queue entirely.